About C4 Therapeutics
C4 Therapeutics is pioneering a new class of drugs. C4’s technology platform produces small molecule drugs that harness machinery already present in cells to selectively target disease-relevant proteins for degradation. Our approach has the potential to address a broad range of diseases including cancer, infectious disease, and autoimmune disorders.
- Develop and execute synthetic routes of target molecules, including work up, purification, isolation, and characterization of products.
- Optimize drug candidates through interpretation of complex data sets through iterative SAR.
- Utilize computational approaches, including structure guided drug design, to optimize chemical leads.
- Work with a multidisciplinary groups to initiate and advance drug discovery programs.
- Manage external study execution at contract research organizations and engage with extramural industry and academic collaborators.
- Contribute to the writing of patents, scientific presentations, and publications.
- Critically analyze data and communicate findings effectively to multidisciplinary team members and senior management.
PhD in organic chemistry with 4+ years of relevant biopharma/pharma experience or BS/MS in organic or medicinal chemistry with a minimum of 10 years of relevant experience, preferably in the biopharma/pharma setting.
- Proven scientific track record of advancing small molecules through stage gate milestones from Hit ID through candidate selection.
- Expertise in synthetic organic chemistry, including methodologies, transformations, and mechanisms.
- Ability to work independently and apply experience and knowledge to solve difficult synthetic challenges and provide useful guidance to other chemists on the project team.
- Strong motivation, independence, and ability to work in a high-pace multidisciplinary, matrix environment with minimal supervision.
- Demonstrated ability to effectively manage and mentor research staff.
- Excellent interpersonal as well as oral and written communication skills required.